Navigation Links
Kewaunee Scientific Reports Record Results Net Earnings for Year Increase 36%, Sales Increase 16%
Date:6/24/2009

5,613 Other income (expense) 8 49 (28) 47 Interest expense (49) 8 (280) (294) ----- ----- ----- ----- Earnings before income taxes 1,623 846 6,776 5,366 Income tax expense 669 342 2,264 1,733 --- --- ----- ----- Earnings before minority interests 954 504 4,512 3,633 Minority interests in subsidiaries (34) (58) (265) (499) ---- --- ----- ----- Net earnings $920 $446 $4,247 $3,134 ==== ==== ====== ====== Net earnings per share Basic $0.36 $0.17 $1.66 $1.24 Diluted $0.36 $0.17 $1.66 $1.23 Weighted average number of Common shares outstanding (in thousands) Basic 2,556 2,551 2,555 2,530 Diluted 2,556 2,577 2,561 2,557

                           Condensed Consolidated Balance Sheets
                                      (in thousands)

                                               April 30         April 30
    Assets                                       2009             2008
                                                 ----             ----
    Cash and cash equivalents                   $3,559          $3,784
    Restricted cash                                456             480
    Receivables, less allowances                24,526          20,087
    Inventories                                  7,839           6,984
    Prepaid expenses and other current
     assets               
'/>"/>
SOURCE Kewaunee Scientific Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Kewaunee Scientific Announces First Quarter Results and Quarterly Dividend
2. Boston Scientific to Explore Sale of Cardiac Surgery and Vascular Surgery Businesses
3. Thermo Fisher Scientific Executive Officers Adopting SEC Rule 10b5-1 Trading Programs
4. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
5. Boston Scientific Amends Credit Facility and Prepays $1 Billion on Loan
6. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
7. Thermo Fisher Scientific to Present at Investor Conferences
8. Boston Scientific to Participate in the Bear Stearns 20th Annual Healthcare Conference
9. Dr. Keith Wilson Named President and Chief Scientific Officer of Takeda San Diego
10. BioLife Solutions Expands Scientific Advisory Board
11. Thermo Fisher Scientific Acquires Instrument Sales Business of Davis Inotek
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... the development and commercialization of a once-daily, oral therapy ... today announced financial results for the period ended June ... , Reported cash and cash equivalents totaling $37.4 ... December 31, 2013.  , Reported a net loss ...
(Date:7/25/2014)... July 25, 2014 Sinovac Biotech Ltd. (Nasdaq: ... China , today announced that it will ... June 30, 2014, after market close on Thursday, August 14, ... to the market opening on Friday, August 15, 2014, at ... China Standard Time) to review the Company,s financial results and ...
(Date:7/24/2014)... 2014 Gain recognition for leadership ... of the biotech industry. Nominations are now being ... to you by the Bio Supply Management ... chain management professionals for the past 7 years. ... the Biotech industry – Manufacturers, Service Providers, Material ...
(Date:7/24/2014)... 24, 2014  ECC West Africa, LLC (ECC) signed ... with University College Hospital (UCH) Ibadan Board of Management ... finance, design, construct, and operate and maintain a new, ... . Under the first of the 4-phase project, ECC ... funding applications. UCH Ibadan intends to finance and develop ...
Breaking Biology Technology:Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Sinovac to Host Conference Call to Report Second Quarter 2014 Unaudited Financial Results 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 2Call for Submission: BSMA’s Supply Chain Management Innovation Awards 3ECC Signs a Contract for the Finance, Design, and Construction of a Premier Cancer Institute in Ibadan, Nigeria 2
... caused by mutations in the gene responsible for making ... and developing new therapies has been hampered by the ... fail to develop many of the symptoms seen in ... April issue of the Journal of Clinical Investigation have ...
... 6 /Xinhua-PRNewswire-FirstCall/ -- Pharmaxis,(ASX: PXS; Nasdaq: PXSL) today ... treat bronchiectasis has been accepted for evaluation by,China,s ... pharmaceutical companies are required to undertake a study ... application.,Approval of the clinical trial application is expected ...
... PALO ALTO, Calif., March 6 Jazz,Pharmaceuticals, Inc. ... the,public to a live webcast of the company,s ... 10:00 a.m. Eastern Time/7:00 a.m.,Pacific Time on Thursday, ... last,approximately two hours., Members of Jazz Pharmaceuticals, ...
Cached Biology Technology:Pharmaxis' First Steps into China 2
(Date:7/24/2014)... -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the ... Phase 3 study of Zerenex (ferric citrate), the Company,s ... of hyperphosphatemia in patients with end-stage renal disease (ESRD) ... delivery with FErric CiTrate in EsrD) was published online ... of Nephrology ( JASN ). , ...
(Date:7/24/2014)... have decreased by 45% on average over a 35 ... a study on the impact of humans on declining ... benefits invertebrates such as insects, spiders, crustaceans, slugs and ... pest control for crops, decomposition for nutrient cycling, water ... Science and led by UCL, Stanford and ...
(Date:7/24/2014)... 3.5 billion years of evolutionary trial and error, is ... may be reaching a tipping point. , In a ... published in Science , an international team of ... is contributing to what appears to be the early ... , Since 1500, more than 320 terrestrial vertebrates have ...
Breaking Biology News(10 mins):Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex™ (ferric citrate) long-term Phase 3 study results published in JASN 4Invertebrate numbers nearly halve as human population doubles 2Invertebrate numbers nearly halve as human population doubles 3Stanford biologist warns of early stages of Earth's 6th mass extinction event 2Stanford biologist warns of early stages of Earth's 6th mass extinction event 3
... of the body, the great majority of genes are silenced, ... up chromosomes. Estimates are that only about 10 percent of ... or "on," at any given time in a particular cell ... , Reliable gene silencing is vital to the health of ...
... have discovered a gene in fruit flies that helps ... The study, published in the April 4 issue of ... in mammals. , In teasing apart the molecular interactions ... gene they dubbed "Lazaro" that is expressed 15 times ...
... industry, including cruise lines, local governments and shore ... are taking proactive measures to ensure a sustainable ... according to a new report titled From Ship ... by Conservation International's (CI) Center for Environmental Leadership ...
Cached Biology News:New mechanism for essential genome-wide gene silencing identified 2New gene reduces retinal degeneration in fruit flies 2Report finds cruise industry is protecting the precious places it visits 2Report finds cruise industry is protecting the precious places it visits 3Report finds cruise industry is protecting the precious places it visits 4
...
Goat polyclonal to Rabenosyn 5 ( Abpromise for all tested applications). Antigen: Synthetic peptide: ELKHTLAKQKGGTD, corresponding to C terminal amino acids 771-784 of Human Rabenosyn 5. Entr...
... ( Abpromise for all tested ... Synthetic peptide derived from residues 231 ... (Note: the amino acid sequence is ... Entrez Gene ID: 80829 ...
Anti-Salmonid Ig (H), Alk Phos, (Clone IPA5F12) (mouse IgG2a)...
Biology Products: